middle.news
How ITM’s Lutetium-177 Supply Deal Could Accelerate Radiopharm’s Cancer Therapies
2:18am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
How ITM’s Lutetium-177 Supply Deal Could Accelerate Radiopharm’s Cancer Therapies
2:18am on Monday 2nd of June, 2025 AEST
Key Points
Supply agreement for non-carrier-added Lutetium-177 finalized
Supports Radiopharm’s clinical programs targeting solid tumors
Key assets RAD 204, RAD 202, and RV01 to utilize ITM’s isotope
ITM holds FDA Drug Master File and EU marketing authorization
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE